I could be wrong (I don't think I am) but I think that at the time of the announcement of the first candidate being enrolled for the P2 GVHD FDA trial, only USA venues were registered?
It might just be me but doesn't management have a responsibility to shareholders to explain why Turkey was added (by an Australian company doing a FDA trial in the USA)? It sounds costly and bizarre to me?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.005(2.86%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 16.5¢ | $41.91K | 247.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 8275 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 3700 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| CYP (ASX) Chart |